KRMD

KORU Medical Systems, Inc. (KRMD) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2025. KORU Medical Systems, Inc. develops, manufactures, and commercializes large volume subcutaneous infusion solutions, primarily for immunoglobulin delivery to treat Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The company operates as a single segment with revenue streams from domestic core, international core, and pharma services/clinical trials.

Key Financial Metrics

Note: The company has a $10 million credit facility (revolving and term) with no outstanding borrowings as of September 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenue increased 27.2% year-over-year. This was driven by a 229.6% surge in International Core revenue, which offset a 5.0% decline in Domestic Core revenue and a 4.4% decline in Pharma Services.
• Margin Compression: Gross margin decreased from 63.4% to 60.2% in Q3 2025. Management attributed this to higher manufacturing costs, geographic sales mix shifts, and tariff-related charges of approximately $0.1 million.
• Expense Management: Operating expenses increased 3.5% to $7.13 million. Selling, General, and Administrative (SG&A) expenses rose 16.9% due to higher compensation/bonuses and legal fees. Conversely, Research and Development (R&D) expenses dropped 39.2% due to lower project spend and prior-year severance costs.
• Improved Profitability: Net loss narrowed significantly by 50.8% in Q3 and 52.3% on a year-to-date basis, primarily due to revenue growth outpacing operating expense increases.
• Working Capital: Inventory increased by $1.6 million year-over-year to $4.41 million, reflecting production build-up. Cash used in operating activities improved to $(0.63) million for the nine months ended Sept 30, 2025, compared to $(1.26) million in the prior year.

Outlook, Risks, and Management Commentary

• Liquidity: Management expects cash on hand ($8.46 million) and operating cash flows to be sufficient for at least the next 12 months. The company maintains a $10 million credit facility as a backup liquidity source.
• Tariff Impact: Newly enacted tariffs are expected to impact gross margins by less than 100 basis points on an annualized basis, though actual results may vary.
• Strategic Drivers: Growth is being driven by new patient starts, share gains in key accounts, and international expansion (specifically prefilled syringe conversions). Domestic revenue was temporarily impacted by a US distributor purchasing from an international distributor.
• Risks: Key risks include dependence on key personnel, regulatory compliance (FDA), reimbursement risks, and the ability to secure additional capital if strategic plans require more funding than current cash reserves allow.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the 229.6% international revenue spike and the extent of the "cross-border" distributor purchase impacting domestic figures.
• Margin Trajectory: Monitor if gross margins stabilize or continue to compress due to tariffs and manufacturing costs.
• Inventory Levels: Assess the $1.6 million increase in inventory to ensure it aligns with demand and does not signal future write-downs.
• Cash Burn: Confirm that the improved operating cash flow (reduced burn) is sustainable as the company scales R&D and SG&A.
• Debt Covenants: Review the amended credit facility terms (maturity extended to late 2026) to ensure compliance with financial covenants.